Concert Pharma (CNCE)
NASDAQ:CNCE
Holding CNCE?
Track your performance easily

Concert Pharma (CNCE) Income Statement

0 Followers

Concert Pharma Income Statement

Last quarter (Q ), Concert Pharma's total revenue was $8.00K, a decrease of -98.53% from the same quarter last year. In Q, Concert Pharma's net income was $-28.90M. See Concert Pharma’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20Dec 19Dec 18Dec 17
Total Revenue
$ 42.00K$ 32.58M$ 7.90M$ 1.08M$ 10.51M$ 143.89M
Cost of Revenue
------
Gross Profit
------
Operating Expense
$ 124.31M$ 110.09M$ 80.55M$ 80.09M$ 66.09M$ 51.24M
Operating Income
$ -124.27M$ -77.51M$ -72.65M$ -79.02M$ -55.58M$ 92.65M
Net Non Operating Interest Income Expense
--$ -2.20M$ 849.00K$ 0.00$ -815.00K
Other Income Expense
$ -2.04M$ -2.54M$ -2.20M$ 849.00K$ -127.00K$ 3.50M
Pretax Income
$ -126.31M$ -80.05M$ -74.85M$ -78.17M$ -55.71M$ 95.34M
Tax Provision
-$ 0.00$ -85.00K$ 0.00$ 313.00K$ -300.00K
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -126.31M$ -80.05M$ -74.77M$ -78.17M$ -56.02M$ 95.19M
Basic EPS
$ -3.21$ -2.33$ -2.40$ -3.29$ -2.40$ 4.20
Diluted EPS
$ -3.21$ -2.33$ -2.40$ -3.29$ -2.40$ 4.06
Basic Average Shares
$ 163.12M$ 34.41M$ 31.20M$ 23.74M$ 23.37M$ 22.64M
Diluted Average Shares
$ 163.12M$ 34.41M$ 31.20M$ 23.74M$ 23.37M$ 23.44M
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 124.31M$ 110.09M$ 80.55M$ 80.09M$ 66.09M$ 51.24M
Net Income From Continuing And Discontinued Operation
$ -126.31M$ -80.05M$ -74.77M$ -78.17M$ -56.02M$ 95.64M
Normalized Income
$ -124.27M$ -77.51M$ -72.56M$ -79.00M$ -55.92M$ 95.70M
Interest Expense
----$ 0.00$ 815.00K
EBIT
$ -124.27M$ -77.51M$ -72.65M$ -79.02M$ -55.58M$ 96.15M
EBITDA
$ -123.00M$ -76.03M$ -71.04M$ -77.35M$ -54.34M$ 97.16M
Currency in USD

Concert Pharma Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis